For years, AbbVie (NYSE: ABBV) was known primarily for immunology. Humira built the company into a pharmaceutical giant, and newer blockbusters Skyrizi and Rinvoq have helped replace much of the revenue lost to biosimilar competition. Now the company's got another iron in the fire -- neuroscience -- and it's no slouch.
Management now expects its neuroscience portfolio to generate approximately $12.7 billion in revenue during 2026, raising guidance by another $100 million after a strong first half of the year. That's a remarkable figure when you consider that the portfolio generated $10.8 billion last year and continues to grow at a double-digit pace. This Rare Signal Is Flashing Again.
In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue » Unlike some pharmaceutical franchises that depend on a single blockbuster, AbbVie's neuroscience business has become increasingly diversified.
During the second quarter, neuroscience revenue climbed 20.3% year over year to $3.23 billion. Schizophrenia and bipolar disorder drug Vraylar generated $1.07 billion, therapeutic Botox contributed $1.04 billion, and migraine drugs Ubrelvy and Qulipta combined for $742 million in quarterly sales. Parkinson's disease therapy Vyalev added another $256 million.
The fastest-growing part of AbbVie's neuroscience business may be migraine. Combined sales rose 22.6% year over year as Ubrelvy and Qulipta continued gaining traction with physicians addressing both acute migraine attacks and migraine prevention. Migraine affects an estimated 1.2 billion people worldwide, yet many patients remain untreated or cycle through multiple therapies before finding one that works.
That leaves considerable room for continued growth, even in an increasingly competitive market. Meanwhile, therapeutic Botox remains one of the most durable assets in AbbVie's portfolio. Beyond its cosmetic applications, Botox is approved for chronic migraine, cervical dystonia, spasticity, overactive bladder, and several other neurological disorders, giving the product multiple avenues for sustained demand.
Extract — continue reading at the source.
